{"nctId":"NCT00337610","briefTitle":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2006-06"},"conditions":["Type 2 Diabetes Mellitus (T2DM)"],"count":190,"armGroups":[{"label":"sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day"]},{"label":"sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day"]}],"interventions":[{"name":"sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day","otherNames":["Januvia"]},{"name":"comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Males\n* Females who are highly unlikely to become pregnant\n* Patients poorly controlled while taking one or two oral antidiabetic medications\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient required insulin therapy within the prior 8 weeks\n* Patient is on or has been taking Thiazolidinediones (TZDs) such as Actos® (pioglitazone) or Avandia® (rosiglitazone) or is on or has been taking Byetta® (exenatide) within the prior 12 weeks of the screening visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 18","description":"A1C was measured as a percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":null},{"groupId":"OG001","value":"0.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 18","description":"Change from baseline at Week 18 is defined as Week 18 FPG minus Week 0 FPG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.0","spread":null},{"groupId":"OG001","value":"-6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2 Hr-PMG at Week 18","description":"Change from baseline at Week 18 is defined as Week 18 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.6","spread":null},{"groupId":"OG001","value":"-13.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in A1C at Week 30","description":"A1C was measured as a percent. Thus, this change from baseline reflects the Week 30 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":96},"commonTop":["Blood Glucose Increased","Nasopharyngitis","Diarrhoea","Pharyngitis"]}}}